Analysts Offer Predictions for BDTX FY2026 Earnings

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) – Investment analysts at HC Wainwright issued their FY2026 earnings per share estimates for shares of Black Diamond Therapeutics in a research report issued to clients and investors on Monday, August 11th. HC Wainwright analyst R. Burns anticipates that the company will post earnings per share of ($1.04) for the year. HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Black Diamond Therapeutics’ current full-year earnings is ($1.30) per share.

Black Diamond Therapeutics (NASDAQ:BDTX) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.06.

Other research analysts have also issued reports about the company. Raymond James Financial upgraded Black Diamond Therapeutics to an “outperform” rating and set a $11.00 price target on the stock in a research report on Tuesday, July 1st. Wall Street Zen lowered Black Diamond Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, August 9th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, Black Diamond Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $12.40.

Black Diamond Therapeutics Stock Up 9.1%

NASDAQ:BDTX opened at $2.77 on Wednesday. Black Diamond Therapeutics has a 12-month low of $1.20 and a 12-month high of $6.75. The firm has a market capitalization of $157.72 million, a P/E ratio of 12.04 and a beta of 2.87. The stock’s fifty day simple moving average is $2.64 and its 200-day simple moving average is $2.15.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. R Squared Ltd bought a new position in Black Diamond Therapeutics during the second quarter worth about $25,000. Wealth Enhancement Advisory Services LLC bought a new position in Black Diamond Therapeutics during the second quarter worth about $28,000. American Century Companies Inc. bought a new position in Black Diamond Therapeutics during the second quarter worth about $30,000. Jump Financial LLC acquired a new stake in shares of Black Diamond Therapeutics in the 2nd quarter valued at about $32,000. Finally, Prudential Financial Inc. acquired a new stake in shares of Black Diamond Therapeutics in the 2nd quarter valued at about $32,000. 95.47% of the stock is currently owned by institutional investors.

Black Diamond Therapeutics Company Profile

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.